Literature DB >> 15634759

Vav transformation requires activation of multiple GTPases and regulation of gene expression.

Todd R Palmby1, Karon Abe, Antoine E Karnoub, Channing J Der.   

Abstract

Although Vav can act as a guanine nucleotide exchange factor for RhoA, Rac1, and Cdc42, its transforming activity has been ascribed primarily to its ability to activate Rac1. However, because activated Vav, but not Rac-specific guanine nucleotide exchange factors, exhibits very potent focus-forming transforming activity when assayed in NIH 3T3 cells, Vav transforming activity must also involve activation of Rac-independent pathways. In this study, we determined the involvement of other Rho family proteins and their signaling pathways in Vav transformation. We found that RhoA, Rac1, and Cdc42 functions are all required for Vav transforming activity. Furthermore, we determined that Vav activation of nuclear factor-kappaB and the Jun NH2-terminal kinase mitogen-activated protein kinase (MAPK) is necessary for full transformation by Vav, whereas p38 MAPK does not seem to play an important role. We also determined that Vav is a weak activator of Elk-1 via a Ras- and MAPK/extracellular signal-regulated kinase kinase-dependent pathway, and this activity was essential for Vav transformation. Thus, we conclude that full Vav transforming activation is mediated by the activation of multiple small GTPases and their subsequent activation of signaling pathways that regulate changes in gene expression. Because Vav is activated by the epidermal growth factor receptor and other tyrosine kinases involved in cancer development, defining the role of aberrant Vav signaling may identify activities of receptor tyrosine kinases important for human oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15634759

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  10 in total

1.  Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Authors:  Brenda L Montalvo-Ortiz; Linette Castillo-Pichardo; Eliud Hernández; Tessa Humphries-Bickley; Alina De la Mota-Peynado; Luis A Cubano; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-03-01       Impact factor: 5.157

Review 2.  Phosphorylation-mediated regulation of GEFs for RhoA.

Authors:  Maulik Patel; Andrei V Karginov
Journal:  Cell Adh Migr       Date:  2013-01-01       Impact factor: 3.405

3.  Vav1 as a central regulator of invadopodia assembly.

Authors:  Gina L Razidlo; Barbara Schroeder; Jing Chen; Daniel D Billadeau; Mark A McNiven
Journal:  Curr Biol       Date:  2013-12-12       Impact factor: 10.834

4.  Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients.

Authors:  Xin Chen; S I Chen; Xiao-An Liu; Wen-Bin Zhou; Rui-Rui Ma; Lin Chen
Journal:  Oncol Lett       Date:  2015-03-02       Impact factor: 2.967

5.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

6.  Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations.

Authors:  Xana Kim-Howard; Celi Sun; Julio E Molineros; Amit K Maiti; Hema Chandru; Adam Adler; Graham B Wiley; Kenneth M Kaufman; Leah Kottyan; Joel M Guthridge; Astrid Rasmussen; Jennifer Kelly; Elena Sánchez; Prithvi Raj; Quan-Zhen Li; So-Young Bang; Hye-Soon Lee; Tae-Hwan Kim; Young Mo Kang; Chang-Hee Suh; Won Tae Chung; Yong-Beom Park; Jung-Yoon Choe; Seung Cheol Shim; Shin-Seok Lee; Bok-Ghee Han; Nancy J Olsen; David R Karp; Kathy Moser; Bernardo A Pons-Estel; Edward K Wakeland; Judith A James; John B Harley; Sang-Cheol Bae; Patrick M Gaffney; Marta Alarcón-Riquelme; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2013-10-26       Impact factor: 6.150

7.  Mutation of Vav1 adaptor region reveals a new oncogenic activation.

Authors:  Lyra Razanadrakoto; Françoise Cormier; Vanessa Laurienté; Elisabetta Dondi; Laura Gardano; Shulamit Katzav; Lionel Guittat; Nadine Varin-Blank
Journal:  Oncotarget       Date:  2015-02-10

8.  The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.

Authors:  Linette Castillo-Pichardo; Tessa Humphries-Bickley; Columba De La Parra; Ingrid Forestier-Roman; Magaly Martinez-Ferrer; Eliud Hernandez; Cornelis Vlaar; Yancy Ferrer-Acosta; Anthony V Washington; Luis A Cubano; Jose Rodriguez-Orengo; Suranganie Dharmawardhane
Journal:  Transl Oncol       Date:  2014-10-24       Impact factor: 4.243

Review 9.  Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.

Authors:  Shulamit Katzav
Journal:  Oncotarget       Date:  2015-10-06

10.  FARP1 boosts CDC42 activity from integrin αvβ5 signaling and correlates with poor prognosis of advanced gastric cancer.

Authors:  Takuro Hirano; Yoshinari Shinsato; Kan Tanabe; Nayuta Higa; Muhammad Kamil; Kohichi Kawahara; Masatatsu Yamamoto; Kentaro Minami; Michiko Shimokawa; Takaaki Arigami; Shigehiro Yanagita; Daisuke Matushita; Yoshikazu Uenosono; Sumiya Ishigami; Yuko Kijima; Kosei Maemura; Ikumi Kitazono; Akihide Tanimoto; Tatsuhiko Furukawa; Shoji Natsugoe
Journal:  Oncogenesis       Date:  2020-02-06       Impact factor: 7.485

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.